Close this search box.

IGC Pharma, INC. About us

We are a focused Clinical-Stage
Pharmaceutical company.

Our Mission Rekindling hope, restoring lives-

Inspired by the needs of patients and families, IGC Pharma relentlessly Cares for a brighter future. We Grow innovative and accessible treatments to transform Alzheimer’s care, empowering patients and families to create a brighter future filled with cherished moments. 

Groundbreaking Affordable Therapies to All

Our commitment extends beyond research and innovation. By introducing affordable therapies, we ensure that advancements are accessible to everyone, regardless of geographic or economic barriers. This is integral to our philosophy of making a global impact on health.

Our Inspired Approach

Our strategic pipeline of drug candidates is at the forefront of our mission:

IGC-AD1 and LMP target the key markers of Alzheimer’s, including neuroinflammation, amyloid-beta (Aβ) plaques, and neurofibrillary tangles. Notably, IGC-AD1 is advancing through a Phase 2 clinical trial to address agitation in dementia due to Alzheimer’s ( Identifier: NCT05543681).

TGR-63 aims to halt the progression of Alzheimer’s by targeting Aβ plaques.

IGC-M3, in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting the early stages of Alzheimer’s.

IGC-1C, also in the preclinical stages, targets tau protein and neurofibrillary tangles, emphasizing our forward-thinking approach to combat Alzheimer’s.

Harnessing Artificial Intelligence in Alzheimer’s Research

IGC Pharma is advancing the integration of artificial intelligence (AI) into our Alzheimer’s research. Our AI initiatives are deeply embedded in our research strategy, allowing us to optimize clinical trials and investigate early detection of Alzheimer’s disease. 

Our use of AI includes the development of advanced algorithms that can analyze vast amounts of data to identify patterns and predict disease progression more effectively. This capability not only improves the accuracy of our clinical trials but also speeds up the process, making it possible to bring new therapies to market faster. In our ongoing Phase II trial of IGC-AD1, AI algorithms play a crucial role in interpreting complex multimodal data collected from patients, facilitating a more personalized understanding of Alzheimer’s disease treatment.